January 9, 2019
Omya develops fast-dissolving, chewable tablets
Omya has developed Omyasprint, an orally disintegrating tablet (ODT) based on the excipient Omyapharm and vitamin B 12.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 8, 2019
Corvus Pharmaceuticals enrolls patients to test combination of two drugs from its programs
Oncology focused pharmaceutical company Corvus Pharmaceuticals has started enrolling patients in the second arm of its ongoing Phase 1/1b dose-escalation study to test combination of CPI-006, a humanized monoclonal antibody directed against CD73, with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.
January 8, 2019
Regen Biopharma’s lead NR2F6 agonist combined with Cannabidiol (CBD) could treat Inflammatory Bowel Disease
Regen BioPharma’s researches have combined its lead NR2F6 small molecule agonist with Cannabidiol (CBD) to provide a dynamic therapy for treating inflammatory bowel disease (IBD), and it could work.
January 8, 2019
Lupin gets first EU licensed treatment in EU for myotonia in adults, hits UK German markets in Q1 2019
Lupin got the EC approval of NaMuscla for reducing myotonia symptoms in adult patients, and has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK.
January 8, 2019
Irish researchers developing new medicine to treat more tuberculosis patients
Royal College of Surgeons in Ireland team of researchers (RCSI) said Tuesday they have developed a new treatment for tuberculosis (TB), a potential practical treatment to be scaled-up and mass-produced for clinical testing.
January 8, 2019
Novartis locks Breakthrough Therapy for crizanlizumab in US, for prevention of sickle pain crises
Novartis has secured its crizanlizumab (SEG101) Breakthrough Therapy designation US Food and Drug Administration (FDA), for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD).
January 8, 2019
Denali, Sanofi start with dosing patients in Phase 1 testing DNL747 in patients with ALS
Denali Therapeutics and Sanofi in partnership have started dosing patients in a clinical Phase 1b study of DNL747 in patients with ALS.
January 7, 2019
Debiopharm breaks up with Allergan over Trelstar sale in Nort America
Swiss-based global biopharmaceutical company Debiopharm Group will break up partnership with Allergan, and will transfer commercialisation licence for Trelstar in the US and Canada.
January 7, 2019
OncoSec and GOG Foundation join forces to study Tavo in women with cervical cancer
OncoSec Medical Incorporated and GOG Foundation will jointly work to conduct a registration-enabled study of Tavo (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150), it was announced on Monday.
January 7, 2019
Mirati and BMS to combine sitravatinib and nivolumab for certain non-small cell lung cancer patients in Mirati’s expected Phase 3 trial
Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.